Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20850802 | 0.79 | BRD4 (0.50) | CRBNBRD4BRD2PLA2G7GRM5 | |
| SCHEMBL6195706 | 0.75 | — | — | |
| SCHEMBL21937438 | 0.73 | CRBN (0.33) | CRBNBRD4BRD2 | |
| SCHEMBL1828050 | 0.71 | MAPT (0.36) | PLA2G7GRM5 | |
| SCHEMBL12601120 | 0.71 | PLA2G7 (0.48) | PLA2G7GRM5SRD5A1 | |
| SCHEMBL20245283 | 0.70 | PLA2G7 (0.50) | PLA2G7ALDH1A1 | |
| SCHEMBL21557290 | 0.70 | BRD4 (0.40) | CRBNBRD4BRD2CYP11B1CYP11B2 | |
| SCHEMBL12601346 | 0.70 | PLA2G7 (0.47) | PLA2G7GRM5 | |
| SCHEMBL28597391 | 0.70 | PLA2G7 (0.34) | PLA2G7GRM5 | |
| SCHEMBL20290275 | 0.70 | CRBN (0.34) | CRBNBRD4BRD2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295182-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-09-21 | — | — | US | disclosed |
| EP-3590929-B1 | SPIRO COMPOUND AND USE THEREOF | MEDSHINE DISCOVERY INC (CN) | 2021-09-15 | — | — | EP | disclosed |
| US-10981900-B2 | Spiro compound and use thereof | MEDSHINE DISCOVERY INC. (CN) | 2021-04-20 | — | — | US | disclosed |
| US-20200048235-A1 | SPIRO COMPOUND AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-02-13 | — | — | US | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-0312291-A2 | Di-or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA | MERCK & CO. INC. (US) | 1989-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048235-A1 | SPIRO COMPOUND AND USE THEREOF | S1PR1, S1PR2, S1PR3 | CRBN 4722/4885BRD4 2627/4885BRD2 3991/4885 |
| US-10981900-B2 | Spiro compound and use thereof | S1PR1, S1PR2, S1PR3 | CRBN 4722/4885BRD4 2627/4885BRD2 3991/4885 |
| US-20230295182-A1 | SPIRO DERIVATIVES OF ALPHA-D-GALACTOPYRANOSIDES | LGALS1, LGALS3, LGALS2 | CRBN 3573/4885BRD4 807/4885BRD2 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.